R. Sinha

Blood · with Cripe · 2006–2010

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom R. Sinha trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Duncan
  2. A. Sutherland

Papers from R. Sinha's perspective

Ordered by how strongly the researchers R. Sinha trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The dawning era of polymer therapeutics (Nature reviews. Drug discovery)
  2. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. (European Journal of Cancer)
  3. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. (Clinical Cancer Research)
  4. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. (Journal of Controlled Release)
  5. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. (Journal of Clinical Oncology)
  6. Quantum dots as luminescent probes in biological systems
  7. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies (Clinical Cancer Research)
  8. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. (Journal of Controlled Release)
  9. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition (Clinical Pharmacokinetics)
  10. Clinical translation of angiogenesis inhibitors (Nature Reviews. Cancer)

Their papers